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Abstract
Background: AMP-activated protein kinase (AMPK) acts as a cellular fuel gauge that responds to
energy stress by suppressing cell growth and biosynthetic processes, thus ensuring that energy-
consuming processes proceed only if there are sufficient metabolic resources. Malfunction of the
AMPK pathway may allow cancer cells to undergo uncontrolled proliferation irrespective of their
molecular energy levels. The aim of this study was to examine the state of AMPK phosphorylation
histologically in primary breast cancer in relation to clinical and pathological parameters.
Methods: Immunohistochemistry was performed using antibodies to phospho-AMPK (pAMPK),
phospho-Acetyl Co-A Carboxylase (pACC) an established target for AMPK, HER2, ERα, and Ki67
on Tissue Micro-Array (TMA) slides of two cohorts of 117 and 237 primary breast cancers. The
quick score method was used for scoring and patterns of protein expression were compared with
clinical and pathological data, including a minimum 5 years follow up.
Results: Reduced signal, compared with the strong expression in normal breast epithelium, using
a pAMPK antibody was demonstrated in 101/113 (89.4%) and 217/236 (91.9%) of two cohorts of
patients. pACC was significantly associated with pAMPK expression (p = 0.007 & p = 0.014
respectively). For both cohorts, reduced pAMPK signal was significantly associated with higher
histological grade (p = 0.010 & p = 0.021 respectively) and axillary node metastasis (p = 0.061 & p
= 0.039 respectively). No significant association was found between pAMPK and any of HER2, ERα,
or Ki67 expression, disease-free survival or overall survival.
Conclusion: This study extends in vitro evidence through immunohistochemistry to confirm that
AMPK is dysfunctional in primary breast cancer. Reduced signalling via the AMPK pathway, and the
inverse relationship with histological grade and axillary node metastasis, suggests that AMPK re-
activation could have therapeutic potential in breast cancer.
Published: 1 September 2009
BMC Cancer 2009, 9:307 doi:10.1186/1471-2407-9-307
Received: 10 March 2009
Accepted: 1 September 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/307
© 2009 Hadad et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:307 http://www.biomedcentral.com/1471-2407/9/307Background
AMP-activated protein kinase (AMPK) is an intracellular
energy-sensing kinase that is inactive unless it has been
phosphorylated by upstream kinases at a specific threo-
nine residue (Thr-172) within the kinase domain. Phos-
phorylation at Thr-172 and consequent activation occurs
in response to metabolic stresses that deplete cellular
energy levels and thus increase the AMP/ATP ratio [1,2].
Activation of AMPK can be assessed using a phosphospe-
cific antibody (anti-pAMPK) that recognizes either cata-
lytic subunit isoform (α1 or α2), but only when
phosphorylated at Thr-172. AMPK is proposed as a "fuel
gauge" that monitors changes in the energy status of cells
[2,3]. It is activated by metabolic stresses that inhibit ATP
production such as glucose deprivation [4], ischaemia [5],
or hypoxia [6], or by stresses that accelerate ATP consump-
tion such as contraction in skeletal muscle [7]. Once acti-
vated, AMPK down-regulates energy-consuming
processes, including cell proliferation, thus ensuring that
these processes only proceed if there are sufficient meta-
bolic resources available [8]. AMPK switches on catabolic
pathways that generate ATP, while switching off biosyn-
thetic pathways and other processes that consume ATP,
and hence has a key role in maintaining energy balance
both at the single cell and the whole body levels [2,9].
One direct downstream target of AMPK is acetyl-Coenzyme
A carboxylase (ACC). In its active, de-phosphorylated form,
ACC catalyzes the conversion of acetyl-CoA to malonyl-
CoA in the de novo lipid synthesis pathway [3,10,11].
When it is inactivated by phosphorylation, a decrease in
malonyl-CoA occurs, thereby increasing the mitochondrial
import and oxidation of long chain fatty acids (LCFAs),
resulting in the generation of ATP [12]. ACC exists as two
isoforms, ACC1/a and ACC2/b, with ACC1 being thought
to produce the pool of malonyl-CoA involved in fatty acid
synthesis, while ACC2 is thought to produce the mitochon-
drial pool that regulates fatty acid oxidation [13,14]. AMPK
phosphorylates ACC1 at multiple residues, although phos-
phorylation at a single serine (Ser-79 in rat and Ser-80 in
human ACC1) accounts for the resulting inactivation
[15,16]. AMPK also inactivates ACC2 [17] via phosphoryla-
tion at the site equivalent to Ser-79 on ACC1 (Ser-221 in
human ACC2). A phosphospecific antibody (anti-pACC)
recognizes both ACC1 and ACC2 phosphorylated at these
sites, and is a widely used marker for AMPK activation. In
isolated hepatocytes from AMPK-α1-/- and -α2-/- double
knockout mice, the signal obtained using this antibody is
completely lost, showing that AMPK is responsible for
phosphorylation at these sites [18].
There is a large body of evidence to support the link
between metabolic disorders, such as obesity and type 2
diabetes, and dysfunctional lipid and energy metabolism
causing increases in circulatory and intracellular fatty
acids [10,12,19]. High levels of fatty acids are toxic to cells
and may cause deleterious metabolic abnormalities
[12,19]. These unwanted effects could be prevented by
activation of AMPK and consequent inactivation of ACC2
in peripheral tissues, leading to an increase in fatty acid
oxidation [12,19]. In addition many cancer cells, includ-
ing many breast tumours, exhibit a markedly increased
rate of fatty acid synthesis [20]. Some breast tumours
express high levels of fatty acid synthase (FAS), a key
enzyme for fatty acid biosynthesis [21]. FAS is up-regu-
lated in about 50% of breast cancers, is an indicator of
poor prognosis, and is associated with the HER2 onco-
gene [22-24]. The drug Orlistat (Xenical™), which was
developed as an inhibitor of gastric and pancreatic lipases
and has been approved for weight loss by the FDA, blocks
breast cancer cell cycle progression, promotes apoptotic
cell death, and transcriptional repression of the HER2
oncogene [25]. In addition to these potentially beneficial
effects of AMPK activation on lipid metabolism, AMPK
would also be expected to directly inhibit cell growth and
proliferation. The major kinase that phosphorylates Thr-
172 on AMPK has been identified to be the tumour sup-
pressor kinase, LKB1 [26,27]. Although LKB1 is also the
upstream kinase for a family of twelve additional AMPK-
related kinases [28,29], many of the tumour suppressor
effects of LKB1 are likely to be mediated by AMPK. For
example, AMPK activation causes a G1-S phase cell cycle
arrest [30,31], while it also inhibits cell growth by switch-
ing off the target-of-rapamycin (TOR) pathway [32,33].
Consistent with the idea that AMPK activation might
inhibit growth of tumour cells were findings that the oral
anti-diabetic drug, metformin, inhibits proliferation of
epithelial cells derived from breast, prostate and ovarian
cancers, an effect that requires both LKB1 and AMPK [34].
These findings may be clinically relevant, because epide-
miological studies show an association between a lower
incidence of cancer, including breast cancer, and met-
formin usage in diabetic patients [35,36].
Despite growing evidence in this arena, little is known
about the state of phosphorylation of AMPK, and its
downstream target ACC, in human breast cancers. Since
malignant cells are likely to have an increased energy
demand and may also experience hypoxia and other met-
abolic stresses, one might speculate that AMPK signalling
would be activated. The objective of the present study was
to evaluate the status of phosphorylation of AMPK and
ACC signalling in human primary breast cancer using
immunohistochemistry, and to correlate this with the
clinical and pathological characteristics of the tumours.
Methods
Patients
A total of 354 primary human breast cancer specimens
were used in this study from two cohorts of patients. ThePage 2 of 9
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sal women (aged 34 - 76; median 51 years) with primary
breast cancer who participated in the Adjuvant Breast
Cancer (ABC) clinical trial from 1992 to 2000 at a single
recruiting centre (NHS Tayside) [37].
The second cohort of patients comprised 237 unselected
pre- and post-menopausal women (aged 28 - 89; median
62 years) with primary, previously untreated breast cancer
who were seen and treated at Tayside University Hospi-
tals, Scotland, from 1997 to 2002. Informed consent was
obtained from each patient prior to tissue acquisition.
Tumour samples from these patients were constructed on
tissue microarray (TMA) slides as described below. Ethics
approval was given by the Tayside Research and Ethics
committee (Ref. 07/S1402/90).
TMA construction
A TMA containing up to six 0.6 mm diameter cores of
invasive tumours and normal breast tissue from the same
patients was constructed using a manual tissue arrayer
(Beecher Instruments Inc., Sun Prairie, WI, USA). Briefly,
haematoxylin and eosin (H&E) stained sections of normal
and tumour tissues were reviewed by a single pathologist.
Areas suitable for inclusion in the TMA were marked on
the slide. Marked slides were matched to their correspond-
ing wax blocks (the donor blocks). The areas of interest
were marked on the wax blocks using a marker pen and
0.6 mm diameter cores of tumour or normal breast tissue
were removed and inserted into a pre-cored hole in a
recipient paraffin block. Cores were inserted in a grid
arrangement. Normal breast tissue cores were constructed
alongside the cancerous cores for every patient. Four
micron TMA sections were cut, mounted onto poly-L-
lysine coated glass slides (VWR International Ltd., Lutter-
worth, UK), and dried for 1 hour at 60°C before being de-
paraffinised in Histoclear (National Diagnostics, Hessle,
UK) and xylene, then run through a graded series of alco-
hol and rehydrated under running water.
Immunohistochemistry (IHC)
pAMPK (Thr-172) monoclonal antibody and pACC (Ser-
79) were purchased from Cell Signaling Technology.
MIB1 (Anti-Ki67) and anti-HER2 monoclonal antibodies
were purchased from Novocastra. Optimal staining condi-
tions such as epitope unmasking, antibody titre, and incu-
bation and visualisation method were validated on
conventional whole tissue sections and TMA fragments.
Positive controls included normal spleen and breast epi-
thelium for pAMPK and pACC, and breast cancer samples
of established ER, HER2 and Ki67. Citric acid buffer, pH
6.0 (10 mM) was used as standard microwave-based anti-
gen retrieval method for all proteins except for pACC. Sec-
tions were immersed in 10 mM Citric acid buffer, pH 6.0
and subjected to microwave in a pressure vessel for 15
min before then processed on a DAKO autostainer using
Vectastatin® ABC kits (Vector Labs, Peterborough, UK)
according to the manufacturer's protocol. Ethylene diami-
netetraacetic acid disodium salt dihydrate (EDTA) (Sigma
product E-5134) for 45 minutes at 94°C was used for
pACC antigen retrieval. Sections were blocked by either
normal goat, horse or rabbit serum containing 10% (v/v)
from stock avidin solution (Vector Labs) for 20 min fol-
lowed by incubation with primary antibody including
10% (v/v) from stock biotin solution (Vector Labs) for 1
hour to reduce non-specific background staining. Follow-
ing incubation with the specific primary antibodies, sec-
tions were incubated with either biotinylated anti-rabbit,
anti-sheep, or anti-mouse antibody for 30 min followed
by Vectastain® Elite ABC reagent for another 30 min. Liq-
uid diaminobenzidine (DAB; Dako) was used as a chro-
mogenic agent for 5 min and sections were counter-
stained with Mayer's haematoxylin. In between each
immunostaining step, slides were washed briefly in Tris
buffered saline (TBS) buffer, pH 7.6.
Scoring
Primary TMA scoring was performed by a single author
(SMH), verified by an experienced consultant pathologist
(SF) and where needed by a specialist breast pathologist
(LJ or CAP) using a Nikon Eclipse E600 light microscope
with DXM 1200 digital camera and Eclipse-Net software,
and Virtual Microscopy in the form of Aperio Technolo-
gies, ScanScope XT and Spectrum Plus using TMA software
version 9.1. Cores were scored at a magnification of ×40
(Figure 1). Any discrepancies were resolved by subsequent
consultation. HER2 immunostaining of cores containing
Strong staining of AMPK in normal breast lobular unit (A) compared to its light staining in tumour cells (B)Figure 1
Strong staining of AMPK in normal breast lobular 
unit (A) compared to its light staining in tumour cells 
(B), examples of a positive Ki67 (C) and HER2 (D).Page 3 of 9
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Table 1: Clinico-pathological characteristics of the patients.
Parameter Cohort 1 [n (%)] Cohort 2 [n (%)] P
N 117 237
Menopausal status at diagnosis
Pre- and peri-menopausal 62 (53) 56 (24) < 0.001*
Post-menopausal 55 (47) 181 (76)
Age (years)
Median (range) 51 (34-76) 62 (28-89) < 0.001~
Tumour size (cm)
≤ 2 61 (57) 88 (37) < 0.001*
> 2 46 (43) 148 (63)
Number of positive lymph nodes
0 48 (41) 127 (54) 0.032*†
0.540*‡
1-3 48 (41) 74 (31)
> 3 21 (18) 36 (15)
Histological grade
1 12 (10) 34 (14) 0.399*†
0.425*‡
2 43 (38) 91 (39)
3 59 (52) 110 (47)
Adjuvant therapy
Endocrine therapy 18 (16) 59 (27) N/A
Chemotherapy and/or Radiotherapy 0 (0) 54 (24)
Endocrine + Chemotherapy 12 (10) 10 (4)
Endocrine + Radiotherapy 45 (38) 70 (31)
Endocrine + Chemo + Radiotherapy 42 (36) 31 (14)
Follow up (months)
Median (range) 73 (9-122) 60 (1-120) < 0.001~
Notes: *2-sided Fisher's Exact Test; ~ Mann-Whitney U-test; †first row versus summation of all other rows; ‡last row versus summation of all other 
rows.
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the US FDA-approved scoring guidelines for the Hercep
Test [52]: non-specific membrane staining = 0, membrane
or cytoplasmic staining in <10% of cells = 1+, specific
membrane staining in >10% of cells = 2+, and strong spe-
cific staining in majority of cells = 3+. HER2 amplification
was confirmed for 2+ and 3+ tumours using FISH (Fluo-
rescence In Situ Hybridization). For Ki67 proliferation
index (the fraction of proliferating cells), ERα, pAMPK
and pACC antibody staining of cores containing tumour
were assessed using a scoring system based on the Quick
Score Method [35]. Immuno-reactivity scored semi-quan-
titatively for both the intensity and the proportion of cells
staining: intensity was given scores 0-3 (no staining = 0;
light staining = 1; moderate staining = 2; strong staining =
3) and proportion was given scores 1-6 (0-4% = 1; 5-20%
= 2; 21-40% = 3; 41-60% = 4; 61-80% = 5; 81-100% = 6).
The two scores were then multiplied to obtain the final
result of 0 - 18. Cores from normal spleen and normal
breast tissue were used as control on each slide.
Statistics
All analyses were performed using Microsoft Excel 2002
SP3 (Microsoft Corporation) and Minitab Release 14.13
(Minitab Inc.). Appropriate choice of χ2 for trend and
Fisher's Exact Test (FET) were used for significance of
expression, and non-parametric survival plots used the
Kaplan-Meier method. When grouping of scores was
required for a statistical method, such as Fisher's Exact
Test, pAMPK scores were grouped as scores 3 versus scores
0 - 2, chosen because normal breast epithelial cell staining
had similar strong staining as the tumour cells scored 3.
The pAMPK results were based on comparing strongly
positive AMPK signalling in tumour cells that scored 3 to
scores of 0 - 2. For Ki67, scores 0 - 2 were grouped against
3 - 6. For HER2, scores 0 - 1 versus 2 - 3 with FISH verifi-
cation of the amplification of the latter group; while for
ERα, scores 0 - 3 (negative) versus 4 - 18 (positive) was
chosen [38]. However, where χ2 for trend was used, the
scores were not dichotomised. The null hypothesis was
rejected at an α level of 10% (p ≤ 0.10), and observations
considered to be marginal (i.e. of scientific interest and
worthy of further investigation) for an α level between 5%
and 10% (p ≤ 0.10) and significant at 5% (p ≤ 0.05).
Results
For the first cohort of the 117 patients, 104 (88.9%) were
infiltrating ductal carcinoma, 3 (2.6%) infiltrating lobular
and 10 (8.5%) mixed or other types. All cases were suc-
cessfully scored for Ki67 and HER2; 3/117 (2.6%) for
pACC, and 4/117 (3.4%) for pAMPK were not evaluable
on the TMAs.
Table 2: The association between AMPK and all clinico-pathological and immunohistochemical data
Cohort 1 Cohort 2
Parameter Positive Negative P Positive Negative P
HER2 Positive 0 14 NS 0 13 NS
Negative 12 87 3 95
Ki67 Positive 4 36 NS 7 95 NS
Negative 8 65 11 111
ACC Positive 7 20 0.007 7 29 0.014
Negative 5 81 12 186
ERα Positive 9 61 NS 12 157 NS
Negative 3 38 7 59
Tumour size (cm) ≤ 2 7 51 NS 9 79 NS
> 2 2 43 10 138
Positive axillary nodes 0 8 39 0.021 15 111 0.087
1-3 2 44 2 71
> 3 0 12 2 35
Histological grade 1 5 7 0.010 6 57 0.021
2 2 39 7 81
3 4 53 5 99
KM overall survival Alive 11 73 NS 11 154 NS
Dead 1 28 4 35Page 5 of 9
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infiltrating ductal carcinoma, 16 (6.7%) infiltrating lobu-
lar carcinoma, and 34 (14.3%) were mixed and other
types. One case (1/237 (0.4%)) was excluded from scor-
ing for pAMPK and 19/237 (8%) for pACC were not eval-
uable (Table 1).
Cytoplasmic staining was seen for pAMPK and, as
expected, nuclear staining for Ki67 and ERα; combined
cell membrane and cytoplasm staining for pACC; cell
membrane strongly and cytoplasm lightly for HER2. Nor-
mal breast epithelium did not stain for Ki67, HER2 or
pACC; however strong staining of normal breast epithelial
cytoplasm was observed for pAMPK (Figure 1A).
Reduced AMPK phosphorylation signal (scores 0 - 2) was
seen in the vast majority of the breast cancer specimens
(101/113 [89.4%] and 217/236 [91.9%] of the first and
second cohort respectively), as light staining of the cyto-
plasm (Figure 1B), compared to strong expression in nor-
mal breast epithelium (score 3). A significant positive
association was seen between pAMPK and pACC signals
(FET: p = 0.007 and 0.014 respectively). Reduced AMPK
phosphorylation signal was associated with higher histo-
logical grade (χ2 for trend = 6.644, df = 1, p = 0.010; and
χ2 for trend = 5.291, df = 1, p = 0.021). AMPK phosphor-
ylation signal reduction was also associated with axillary
node metastasis (FET: p = 0.061 and 0.039 respectively)
(Table 2 and additional file 1)
Ki67 expression (Figure 1C) was negatively associated
with ER status (FET: p = 0.002 and p < 0.001 respectively)
(see additional file 1). It was also associated with higher
grade tumours (FET: p < 0.001 in both cohorts), increased
tumour recurrence (FET: p = 0.041 and 0.005, Relative
Risk (RR) = 1.89 and 1.59, Odds Ratio (OR) = 2.39 and
2.47, respectively) and lower overall survival (Kaplan-
Meier Log Rank Test: p = 0.023 and 0.015, RR = 1.62 and
2.13, OR = 2.29 and 23.39, respectively) (Figure 2).
HER2 amplification, found in 11.9% (14/117) and 13.9%
(32/230) of patients respectively (Figure 1D), was signifi-
cantly associated with Ki67 expression (FET: p = 0.006
and 0.021 respectively), higher histological grade (FET: p
= 0.073 and < 0.001 respectively), and inversely with ER
status (FET: p = 0.006 and 0.001 respectively). HER2 pos-
itive patients had increased recurrence (FET: p = 0.027 and
0.001, RR = 1.72 and 1.96, OR = 3.75 and 7.2, respec-
tively); and lower overall survival (Kaplan-Meier Log Rank
Test: p < 0.001 and 0.075, RR = 2.81 and 1.99, OR = 5.19
and 2.3, respectively) (Figure 3).
ER positive tumours, identified in 62.6% (72/115) and
73% (173/237) of patients respectively, were associated
with HER2 negative (FET: p = 0.006 and 0.001 respec-
tively), low Ki67 expression (FET: p = 0.002 and < 0.001
respectively), lower grade tumours (FET: p = 0.029 and <
0.001 respectively), and lower disease recurrence (FET: p
= 0.033 and < 0.001, RR = 1.41 and 2.75, OR = 2.33 and
4.36, respectively). In the second cohort of patients, ER
positive patients also lived longer (Kaplan-Meier Log
Rank Test: p < 0.001, RR = 1.44, OR = 5.81) (Figure 4).
Discussion
Malignant transformation of cells is characterized by
insensitivity to growth-inhibitory signals, unlimited repli-
cative potential, angiogenesis, tissue invasion and metas-
tasis [38]. Despite the physiological stresses in cancer
cells, and the associated hypoxia in both primary and met-
astatic cancer [39], malignant cells continue to proliferate
and invade. These hallmark characteristics of cancer raise
the question of whether dysfunction of AMPK could have
a role in malignancy. The aim of this study was to evaluate
phosphorylation of AMPK and ACC as markers of AMPK
signalling in human breast cancer in relation to clinical
and pathological data.
Kaplan-Meier Survival analysis correlating Ki67 expression to over ll survival in both cohorts (p = 0.023 and p = 0.015 respectively)Figure 2
Kaplan-Meier Survival analysis correlating Ki67 
expression to overall survival in both cohorts (p = 
0.023 and p = 0.015 respectively).Page 6 of 9
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ously reported breast cancer populations as exemplified
by the associations between HER2 amplification, Ki67
expression, ER negative cancers, higher histological grade,
Ki67 labelling index [40] and higher disease recurrence
and lower overall survival. The significant differences in
menopausal status, age, tumour size and node status
between the two cohorts (Table 1) perhaps emphasizes
the consistent trends and significant associations of AMPK
signalling with node status and tumour grade respectively
(Table 2). Further possible caveats include the use of IHC
rather than western blotting to assess the signalling path-
ways, although the distribution of signalling in normal
and cancerous tissues on IHC allowed localisation of the
proteins.
Despite the high energy consuming processes of uncon-
trolled cellular proliferation in breast cancer, the histolog-
ical evidence suggests that AMPK does not seem to
respond in primary breast cancer. In contrast, normal
breast epithelium demonstrated appropriate AMPK stain-
ing, but as expected for a quiescent epithelium no activa-
tion of ACC. Reduced signalling of AMPK
phosphorylation in the majority of the breast cancer spec-
imens (89.4% in the first and 91.9% in the second cohort)
compared to strong expression in normal breast epithelial
cells, and the inverse relationship between staining with
histological grade and node status supports the current
view that activating this energy-sensing enzyme may be a
potential therapeutic avenue in breast cancer [8]. Lower
tumour growth fraction, assessed by lower Ki67 prolifera-
tion index in patients with activated ACC, a downstream
target of AMPK, is consistent with in vitro evidence that
AMPK activation leads to reduced proliferation [41] and
growth inhibition in epithelial cells [34], also associated
with decreased mTOR signalling [42,43]. AMPK activa-
tion is known to lead to inhibition of the mTOR pathway
[44,45] through phosphorylation of TSC2 [32] and Rap-
tor [33]. Activation of AMPK also directly limits transla-
tional initiation and protein synthesis through inhibition
of translation elongation factor 2 (EF2) [46]. In this study
we have focused on histological evidence for AMPK phos-
phorylation and its direct downstream target, ACC, as
markers of AMPK activation, and have correlated them
Kaplan-Meier Survival Curve correlating ER status to overall survival in both cohorts (p = 0.102 nd < 0.001 respectively)Figure 4
Kaplan-Meier Survival Curve correlating ER status to 
overall survival in both cohorts (p = 0.102 and < 0.001 
respectively).
Kaplan-Meier survival analysis correlating HER2 status to over ll survival in both cohorts (p < 0.001 and = 0.075 respectiv ly)Figure 3
Kaplan-Meier survival analysis correlating HER2 sta-
tus to overall survival in both cohorts (p < 0.001 and 
= 0.075 respectively).Page 7 of 9
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breast cancer: ER, Ki67 and HER2.
Conclusion
In conclusion, the role of AMPK in the mechanism of
action of metformin [47-49], evidence in support of a
putative relationship between type 2 diabetes and neopla-
sia with particular reference to breast cancer [50], and the
reduced risk of cancer in patients with type 2 diabetes tak-
ing metformin compared with those on other medica-
tions such as sulphonylureas [35,51], are all indicative of
the need to explore this relationship and its potential to
discover a novel targeted therapy in breast cancer. AMPK
activation is a possible therapeutic target for cancers, since
AMPK inhibits mTOR signalling, which in turn inhibit
tumour growth in vitro and metastasis in experimental
animal models [20]. The data presented here, the first
immunohistochemical evidence of AMPK dysfunction in
primary breast cancer supports further laboratory and
clinical research targeting AMPK by metformin or its ana-
logues in breast cancer.
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